Historic Ten-Cent Drug Slashes Heart Failure Hospitalisations by a Quarter
Groningen, Tuesday 12 May 2026
Dutch researchers have revealed that digoxin, an ancient medication costing under €0.10 daily, reduces heart failure hospitalisations by 25%, potentially transforming future cardiovascular treatment guidelines and healthcare economics.
A Botanical Legacy Re-evaluated
Heart failure currently affects approximately 500,000 individuals in the Netherlands, a demographic figure projected to rise steadily in the coming years [3][4][8]. Patients typically suffer from severe breathlessness, chronic fatigue, and recurrent hospital admissions as a direct consequence of the heart’s diminished pumping capacity [8]. The contemporary standard of care relies heavily on a combination of four medications, colloquially known within the medical community as the ‘Fantastic Four’: angiotensin receptor neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors [4][5]. However, the physiological burden of heart failure triggers compensatory mechanisms, causing the body to release stress hormones such as adrenaline; while this temporarily stimulates the heart, it effectively overworks and damages the cardiac muscle over the long term [3][5].
Rigorous Clinical Validation
On 11 May 2026, a research consortium led by University Medical Center Groningen (UMCG) cardiologists Dirk Jan van Veldhuisen, Kevin Damman, and Peter van der Meer presented ground-breaking findings at the ESC Heart Failure Congress in Barcelona, alongside dual publications in the prestigious journals Nature Medicine and JAMA [4][7]. Supported by a €3 million investment from the Hartstichting and ZonMw, the researchers conducted a robust clinical evaluation to determine if low-dose digoxin could serve as an effective fifth pillar of cardiovascular treatment [4][5]. The primary investigation spanned 43 Dutch hospitals, monitoring 1,000 patients over an average period of three years [3][5].
Economic Paradigm Shift in Healthcare
Beyond its clinical efficacy in suppressing detrimental stress hormones, digoxin presents a profound economic advantage for systemic healthcare expenditure [5][8]. The repurposed botanical extract costs less than €0.10 per day, standing in stark contrast to modern heart failure medications that routinely cost several euros daily [3][6][8]. Professor van Veldhuisen has pointedly noted that the pharmaceutical industry lacks the financial incentive to promote such an ancient remedy, stating that there is no profit margin to be extracted from its widespread use [3].